Related Experiment Video

Updated: Jun 4, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Tumor biology and prognostic factors in renal cell carcinoma

David S Finley1, Allan J Pantuck, Arie S Belldegrun

  • 1Institute of Urologic Oncology, UCLA David Geffen School of Medicine, Los Angeles, California 90095-1738, USA.

The Oncologist
|February 25, 2011
PubMed

Insights

Advances in understanding renal cell carcinoma (RCC) tumor biology, including vascular endothelial growth factor (VEGF) and mTOR pathways, have led to targeted therapies. Despite progress, managing metastatic RCC requires better risk stratification and personalized treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Significant advancements in understanding renal cell carcinoma (RCC) tumor biology over the last 15 years.
  • Identification of key dysregulated signaling pathways, including vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR), in RCC development and progression.

Purpose of the Study:

  • To review breakthroughs in the genetic alterations and signaling pathways underlying RCC pathogenesis.
  • To highlight the development of prognostic factors, risk stratification nomograms, and predictive biomarkers for individualized treatment.

Main Methods:

  • Review of recent scientific literature and clinical trial data.
  • Analysis of genetic alterations and signaling pathway dysregulation in RCC.
  • Evaluation of prognostic factors and biomarkers for risk stratification and treatment selection.

Main Results:

  • Targeted pharmaceutical agents based on VEGF, VEGFR, and mTOR pathways have shown survival benefits, especially in clear cell RCC.
  • Despite effective therapies, metastatic RCC invariably progresses, underscoring the need for improved risk assessment.
  • Development of comprehensive nomograms and predictive biomarkers aids in stratifying patient risk and personalizing treatment.

Conclusions:

  • Understanding RCC tumor biology has enabled targeted therapy development with demonstrated clinical benefits.
  • Effective management of metastatic RCC necessitates precise patient risk stratification and individualized treatment approaches.
  • Continued research into genetic alterations and biomarkers is crucial for optimizing patient outcomes in RCC.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...